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  P
renatal and postnatal exposure 
to persistent organochlorine 
pollutants, such as 
polychlorinated biphenyls (PCBs), has 
been implicated as a possible cause of 
impaired immune function in children. 
For example, studies have shown that 
children who have been exposed 
to PCBs and related compounds 
from their mothers’ contaminated 
diets have reduced concentrations 
of immunoglobulins and increased 
frequency of childhood infections [1–
3]. And a new study by Heilmann et al. 
published in   PLoS Medicine   shows that 
children exposed to PCBs have reduced 
antibody responses to childhood 
vaccinations, adding to the growing 
evidence that PCBs are associated 
with developmental immunotoxicity 
(DIT) [4]. The study provides a stark 
example of the heightened immune 
vulnerabilities that exist during early 
life and that must be adequately 
protected from environmental insult 
if we are to minimize health risks to 
children. 
  The  New  Study
    In their prospective epidemiological 
study, Heilmann and colleagues 
studied two birth cohorts from the 
Faroe Islands. These islands are a 
unique setting for studies of PCB 
immunotoxicity because average PCB 
exposures are up to 10-fold higher than 
average levels in Northern Europe, due 
to the traditional habit of eating pilot 
whale blubber. Heilmann et al. assessed 
PCB exposure perinatally by using 
quantitation of major PCB congeners 
(components) in pregnancy serum, 
transition milk (produced immediately 
following colostrum secretion), and 
children’s serum. Following routine 
childhood vaccinations with two T 
cell–dependent vaccines (tetanus and 
diphtheria), children were examined 
at 18 months and at seven years, and 
serum was analyzed for tetanus and 
diphtheria toxoid antibodies and for 
PCBs. The researchers found that 
prenatal and perinatal PCB levels 
were excellent predictors of antibody 
responses to the vaccines (for example, 
antibody response to diphtheria 
toxoid decreased at age 18 months by 
24.4 percent [95 percent conﬁ  dence 
interval, 1.63–41.9] for each doubling 
of the cumulated PCB exposure at the 
time of examination). 
    It is interesting that early-exposure 
PCB levels were better predictors of 
antibody response to vaccines at seven 
years of age than were contemporary 
PCB levels, despite the capacity of 
PCBs to be retained in fatty tissues. 
This suggests that even transitory early-
life exposures to an immunotoxicant 
have the potential to produce immune 
problems in later life. Furthermore, 
one should not assume that toxicant 
body burdens determined at the time 
of immune assessment represent 
effective correlates for DIT. 
    In Heilmann and colleagues’ 
study, PCB exposure was negatively 
associated with antibody responses to 
the immunizations. For example, even 
after receiving a booster vaccination, 
more than 20 percent of the children 
from one cohort had antibody titers 
to diphtheria below the level needed 
for long-term protection. Based on 
the results, the authors suggested 
that even low- to moderate-level PCB 
exposures are likely to inﬂ  uence 
childhood immunization responses. 
This is consistent with the ﬁ  ndings 
of Marchant et al. [5], who showed 
that environmental factors contribute 
signiﬁ  cantly to the persistence 
and avidity maturation (increased 
antibody binding strength) of antibody 
responses during childhood vaccine 
responses.
    Implications of the Study 
    The study results have three important 
implications. First, Heilmann et al. used 
a very valuable measure of DIT, namely, 
a T cell–dependent functional immune 
response [6]. Using this response is 
valuable because immunotoxicity in 
early life can result in major shifts in 
immune function capacity without 
necessarily producing profound 
loss or alteration of immune cell 
populations [7,8]. For this reason, we 
should be cautious about depending 
on circulating leukocyte proﬁ  les to 
detect DIT. Heilmann and colleagues’ 
use of functional immune measures 
is to be applauded and should be 
used whenever possible in assessing 
early-life immunotoxicity. In a recent 
review on the topic, Luster et al. [9] 
discussed the challenges of detecting 
subtle, yet functionally important, 
immune alterations in children. These 
authors suggested that the optimum 
methodology for detecting DIT in 
humans would include an evaluation 
of functional responses to childhood 
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vaccinations. Therefore, Heilmann and 
colleagues’ study serves as a prototype 
that will hopefully lead to other studies 
of the relationship between exposure 
to chemicals and drugs and childhood 
immunization responses.
    A second implication of the 
study is that there are likely to be 
more examples of environmental 
exposure to drugs and/or chemicals 
causing immune dysfunction and/
or targeted immunosuppression 
across a population than examples 
of such exposure causing profound 
immunodeﬁ  ciency. In the era of 
AIDS as a prototype example of 
immunosuppression, we have tended 
toward the default assumption that 
immunosuppression is associated with 
readily detectable losses of circulating 
immune cells. But this is probably 
the exception rather than the rule. 
For example, even with the profound 
loss of cell-mediated immunity 
associated with heavy metal–induced 
Th1-dependent immunosuppression, 
only minimal changes in immune 
cell populations are detectable [7]. 
Ineffective responses to vaccines 
affecting particular segments of the 
population and/or immune-associated 
increases in the incidence of allergic 
disease or asthma are current public 
health issues [10,11], and we must 
identify causative environmental agents 
associated with such changes. But prior 
to the current study by Heilmann et 
al., we have had far too few studies 
designed with prospective assessment 
that included the necessary functional 
measures to detect associations between 
exposure to environmental toxins and 
immune dysfunction.
    A third ramiﬁ  cation of the study’s 
results applies more broadly to 
current regulatory approaches for 
protecting children’s health. Recent 
studies established that the developing 
immune system is a far more sensitive 
target for immunotoxicity than 
that of the adult [7,8,12]. In fact, 
for PCB-related dioxin exposure 
in rodents, there appears to be an 
approximately 100-fold difference 
in dose sensitivity across age groups 
[12]. Studies conducted to date show 
that early-life stages are sensitive to 
far lower levels of immunotoxicants 
than adults, and the toxic effects 
are more extensive and persistent 
following perinatal exposure than 
adult exposure. Additionally, toxicity 
testing using adults is ineffective in 
predicting the immunotoxic risk to 
children following early-life exposure 
[8]. This realization occurs at a 
time when we have witnessed recent 
increases in immune-related childhood 
diseases such as asthma [13]. Recent 
consensus workshops have attributed 
the increased incidence of childhood 
asthma largely to environmental causes 
[11,14], and, in turn, environmental 
factors that are protective during early 
life have also been identiﬁ  ed through 
recent research [15]. 
  Protecting  Children’s  Health
    Regrettably, these research advances 
have not yet been applied to improved 
regulatory protection of children’s 
health. This gap between research 
results and actual health protection 
needs to be closed. DIT testing is not 
currently required to ensure that 
gestational and neonatal exposure 
to drugs and chemicals is safe for the 
child’s immune system. Some clinicians 
and parents are probably unaware 
that most previously approved drugs 
and chemicals were never tested for 
developmental immunotoxic potential, 
and that those currently under 
consideration for approval are not 
required to be tested based on recent 
guidelines [16]. In light of the current 
ﬁ  ndings [4], as well as studies showing 
the vulnerability of the developing 
immune system [12], it seems time to 
reconsider the wisdom of exposing 
pregnant women, infants, and children 
to drugs and chemicals with unknown 
developmental immunotoxic risks.   
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